NLRP3 and metabolic dysfunction-associated steatohepatitis: Blocking the activation of the inflammasome [nucleotide-binding oligomerization domain leucine-rich repeat and pyrin domain containing 3 (NLRP3)] and caspase-1 can reduce the progression of NASH [2].